Table of Content

Table of Contents

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market by Value
2.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type
2.2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market by Value (%)
2.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market by Production
2.3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production by Type
2.3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market by Production (%)

3. The Major Driver of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry
3.1 Historical & Forecast Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Demand
3.2 Largest Application for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy (2018-2028)
3.3 The Major Downstream Company in China Market 2022

4. Global and Regional Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
4.4 Mergers & Acquisitions, Expansion Plans

5. US Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Production Breakdown by Application
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

6. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Production Breakdown by Application
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

7. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Production Breakdown by Application
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

8. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Production Breakdown by Application
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

9. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Production Breakdown by Application
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

10. Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Production Breakdown by Application
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

11. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Production Breakdown by Application
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

12. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Average Price Trend
12.1 Market Price for Each Type of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in US (2018-2022)
12.2 Market Price for Each Type of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Europe (2018-2022)
12.3 Market Price for Each Type of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in China (2018-2022)
12.4 Market Price for Each Type of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Japan (2018-2022)
12.5 Market Price for Each Type of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in India (2018-2022)
12.6 Market Price for Each Type of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Korea (2018-2022)
12.7 Market Price for Each Type of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Southeast Asia (2018-2022)

13. Industrial Chain (Impact of COVID-19)
13.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy

14. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Competitive Landscape
14.1 BioMarin Pharmaceutical
14.1.1 BioMarin Pharmaceutical Company Profiles
14.1.2 BioMarin Pharmaceutical Product Introduction
14.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 Sangamo Therapeutics
14.2.1 Sangamo Therapeutics Company Profiles
14.2.2 Sangamo Therapeutics Product Introduction
14.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 Amicus Therapeutics
14.3.1 Amicus Therapeutics Company Profiles
14.3.2 Amicus Therapeutics Product Introduction
14.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 Roche
14.4.1 Roche Company Profiles
14.4.2 Roche Product Introduction
14.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 Pfizer
14.5.1 Pfizer Company Profiles
14.5.2 Pfizer Product Introduction
14.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 NightstaRx
14.6.1 NightstaRx Company Profiles
14.6.2 NightstaRx Product Introduction
14.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 MeiraGTx
14.7.1 MeiraGTx Company Profiles
14.7.2 MeiraGTx Product Introduction
14.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 Sarepta Therapeutics
14.8.1 Sarepta Therapeutics Company Profiles
14.8.2 Sarepta Therapeutics Product Introduction
14.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 Neurocrine Biosciences
14.9.1 Neurocrine Biosciences Company Profiles
14.9.2 Neurocrine Biosciences Product Introduction
14.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 Voyager Therapeutics
14.10.1 Voyager Therapeutics Company Profiles
14.10.2 Voyager Therapeutics Product Introduction
14.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue (2018-2022)
14.10.4 Strategic initiatives
14.11 Asklepios Biopharmaceutical
15. Conclusion
16. Methodology and Data Source

List of Figure

List of Tables and Figures

Figure 1. Total Demand by Application of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry (Volume)
Figure 2. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2022
Figure 5. US Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, by Type (Million USD) (2018-2028)
Table 4. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, by Type (K Unit) (2018-2028)
Table 5. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Demand (K Unit) by Application (2018-2028)
Table 6. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. BioMarin Pharmaceutical Profiles
Table 61. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Introduction
Table 62. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (Unit), Revenue (Million USD) (2018-2022)
Table 63. BioMarin Pharmaceutical Strategic initiatives
Table 64. Sangamo Therapeutics Profiles
Table 65. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Introduction
Table 66. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (Unit), Revenue (Million USD) (2018-2022)
Table 67. Sangamo Therapeutics Strategic initiatives
Table 68. Amicus Therapeutics Profiles
Table 69. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Introduction
Table 70. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (Unit), Revenue (Million USD) (2018-2022)
Table 71. Amicus Therapeutics Strategic initiatives
Table 72. Roche Profiles
Table 73. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Introduction
Table 74. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (Unit), Revenue (Million USD) (2018-2022)
Table 75. Roche Strategic initiatives
Table 76. Pfizer Profiles
Table 77. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Introduction
Table 78. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (Unit), Revenue (Million USD) (2018-2022)
Table 79. Pfizer Strategic initiatives
Table 80. NightstaRx Profiles
Table 81. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Introduction
Table 82. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (Unit), Revenue (Million USD) (2018-2022)
Table 83. NightstaRx Strategic initiatives
Table 84. MeiraGTx Profiles
Table 85. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Introduction
Table 86. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (Unit), Revenue (Million USD) (2018-2022)
Table 87. MeiraGTx Strategic initiatives
Table 88. Sarepta Therapeutics Profiles
Table 89. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Introduction
Table 90. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (Unit), Revenue (Million USD) (2018-2022)
Table 91. Sarepta Therapeutics Strategic initiatives
Table 92. Neurocrine Biosciences Profiles
Table 93. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Introduction
Table 94. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (Unit), Revenue (Million USD) (2018-2022)
Table 95. Neurocrine Biosciences Strategic initiatives
Table 97. Voyager Therapeutics Profiles
Table 98. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Introduction
Table 99. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (Unit), Revenue (Million USD) (2018-2022)
Table 100. Voyager Therapeutics Strategic initiatives
Table 101. Asklepios Biopharmaceutical Profiles
Table 102. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Introduction
Table 103. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (Unit), Revenue (Million USD) (2018-2022)
Table 104. Asklepios Biopharmaceutical Strategic initiatives